Jun 17, 2020
Emgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine
Jun 16, 2020
Lilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications
May 18, 2020
Theranica Expands Executive Team Amid Growing US Demand for Its FDA-authorized Migraine Treatment Wearable Device
May 07, 2020
Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business Developments
Apr 07, 2020
Frontiers in Neurology Publishes Study Evaluating Remote Electrical Neuromodulation (REN) As Viable Alternative to Drugs for Acute Migraine
Apr 07, 2020
Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC(TM) ODT
Apr 06, 2020
Theranica Expands Access to Prescribed Migraine Wearable Nerivio(TM) Through Partnership With UpScript Health Telemedicine Platform
Mar 30, 2020
Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC(TM), Dosed Every Other Day, for the Preventive Treatment of Migraine
Mar 17, 2020
CEFALY Technology Launches Buy Back Program Where Customers in US and Canada May Return Their Headband-Like Migraine Device and Receive a Discount to Upgrade to the CEFALY DUAL
Feb 25, 2020
eNeura, Inc. Announces Hire of Donald Pearl as Chief Executive Officer
Feb 25, 2020
Theranica Expands Accessibility of Nerivio(TM) to U.S. Migraine Patients Via Partnership With Telemedicine Platform, Cove
Dec 04, 2019
Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine
Nov 20, 2019
Impel NeuroPharma Announces Publication Of Narrative Review In The Journal Headache Supporting Need For Novel Formulations Of Dihydroergotamine (DHE) In Addressing Acute Treatment Of Migraine
Nov 18, 2019
Theranica Announces U.S. Recycling Partnership in Commitment to Sustainable Medical Device Production
Oct 11, 2019
Lilly's REYVOW(TM) (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
Oct 11, 2019
FDA approves new treatment for patients with migraine
Oct 07, 2019
Desperate For A Do-Over? New "Take Two" Campaign By Excedrin® Offers Migraine Sufferers A Second Chance To Re-Live Milestone Moments Marred By Migraines
Sep 05, 2019
Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society
Sep 03, 2019
Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine
Sep 03, 2019
Global Migraine Drugs Market Report 2019: Analysis (2009-2018) & Outlook (2019-2025)